Page last updated: 2024-11-06

benz(cd)indol-2(1h)-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

benz(cd)indol-2(1H)-one: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID67222
CHEMBL ID217045
SCHEMBL ID302763
MeSH IDM0572089

Synonyms (52)

Synonym
HMS1771P10
AC-19763
EN300-17251
2-azatricyclo[6.3.1.0,4,12]dodeca-1(12),4,6,8,10-pentaen-3-one
benzo[cd]indol-2(1h)-one
nsc25094
naphthostyril
naphtholactam
1-naphthalenecarboxylic acid, lactam
2(1h)-peri-naphthazolone
2(1h)-perinaphthazolone
naftostiril
nsc-25094
1,8-naphtholactam
benz[cd]indol-2(1h)-one
130-00-7
EU-0068153
inchi=1/c11h7no/c13-11-8-5-1-3-7-4-2-6-9(12-11)10(7)8/h1-6h,(h,12,13
1-naphthalenecarboxylic acid, 8-amino-, lactam
benz(cd)indol-2(1h)-one
ai3-16690
nsc 25094
einecs 204-973-4
benz[cd]indol-2(1h)-one, technical grade
B3023
CHEMBL217045
FT-0658551
AKOS000119151
(2s)-2-methyl-4-[(2r,8r,11r)-2,8,11-trihydroxy-11-[(5r)-5-[(1r)-1-hydroxypentadecyl]tetrahydrofuran-2-yl]undecyl]-2h-furan-5-one
A805996
ec 204-973-4
F1113-0546
PS-4441
2-azatricyclo[6.3.1.0^{4,12}]dodeca-1(11),4,6,8(12),9-pentaen-3-one
STL363233
SCHEMBL302763
benz[cd]indole-2(1h)-one
benz[cd]indol-2-(1h)-one
1h-benz[cd]indol-2-one
1,2-dihydrobenzo[cd]indol-2-one
benz[cd]-indol-2(1h)-one
DTXSID5059610
mfcd00009748
Q-200094
sr-01000400053
SR-01000400053-1
Z56899189
I11516
1h-benzo[cd]indol-2-one
Q27451626
SY036409
CS-0046300
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID273433Inhibition of Trypanosoma brucei brucei growth2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase.
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's7 (87.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]